B. Braun Receives FDA Clearance for AQUAbase nX
B. Braun, a leader in smart infusion therapy and pain management, announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA for its AQUAbase nX Reverse Osmosis System.
AQUAbase nX is a chemical-free single-stage reverse osmosis device that delivers high-quality water for dialysis patients. With its distinctive design, AQUAbase nX achieves a raw water conversion rate of up to 75%. Furthermore, this could lead to water conservation and cost reduction in power, pre-treatment, and equipment maintenance.
The system, which ranges in capacity from 250 L/h to 750 L/h, has a full stainless steel piping designed to achieve the lowest possible dead space in the main ring. This may prevent microbial contamination. Moreover, the system’s touchscreen display, measuring seven inches, offers direct access to relevant settings and features an up-to-date status bar. AQUAbase nX is a compact and customizable solution suitable for hospitals, dialysis centers, or skilled nursing facilities. In addition, it caters to locations with a range of five to 18 chairs for dialysis patients.
“We are excited to broaden our portfolio of high-quality hemodialysis products with the AQUAbase nX,” said Jonathan Stapley, Senior Director of Marketing, Active Devices. “We now have a compact solution for smaller facilities that has heat disinfection to reduce the need for chemicals.”
In addition to its expertise in infusion therapy, the company is a frontrunner in developing safe and efficient pharmacy products and sustainable healthcare solutions. The company is driven by its mission to assist healthcare providers in continually enhancing patient satisfaction and outcomes. The company has a workforce of 8,500 individuals across over 30 North American locations. On a global scale, the B. Braun Group of Companies employs over 64,000 personnel in 64 countries.
